Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Get Free Report)’s stock price reached a new 52-week high on Wednesday. The stock traded as high as $17.05 and last traded at $17.00, with a volume of 143,390 shares trading hands. The stock had previously closed at $16.80.
Analysts Set New Price Targets
XERS has been the subject of a number of research reports. Wall Street Zen upgraded Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 7th. Leerink Partners lifted their target price on Xeris Biopharma from $12.00 to $16.00 and gave the company an “outperform” rating in a research note on Thursday, September 10th. Barclays upped their target price on Xeris Biopharma from $14.00 to $18.00 and gave the company an “overweight” rating in a report on Wednesday, November 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Xeris Biopharma in a research report on Wednesday, November 4th. Finally, HC Wainwright raised their price target on shares of Xeris Biopharma from $10.00 to $18.00 and gave the stock a “buy” rating in a report on Friday, November 6th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Xeris Biopharma has an average rating of “Moderate Buy” and a consensus price target of $17.00.
Read Our Latest Research Report on XERS
Xeris Biopharma Trading Up 2.4%
The company has a debt-to-equity ratio of 3.89, a current ratio of 2.15 and a quick ratio of 1.58. The company has a fifty day moving average of $10.73 and a 200-day moving average of $7.93. The firm has a market capitalization of $3.14 billion, a PE ratio of -343.21 and a beta of 0.61.
Xeris Biopharma (NASDAQ:XERS – Get Free Report) last issued its earnings results on Thursday, November 5th. The company reported $0.06 EPS for the quarter, beating analysts’ consensus estimates of $0.03 by $0.03. Xeris Biopharma had a positive return on equity of 147.75% and a negative net margin of 1.76%. The firm had revenue of $107.23 million for the quarter, compared to the consensus estimate of $101.68 million. On average, sell-side analysts anticipate that Xeris Biopharma Holdings, Inc. will post 0.15 earnings per share for the current fiscal year.
Insider Buying and Selling at Xeris Biopharma
In other Xeris Biopharma news, insider Kevin McCulloch sold 25,000 shares of the business’s stock in a transaction dated Thursday, November 5th. The stock was sold at an average price of $12.49, for a total value of $312,250.00. Following the completion of the sale, the insider owned 1,559,208 shares of the company’s stock, valued at $19,474,507.92. The trade was a 1.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Steven Pieper sold 5,000 shares of Xeris Biopharma stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $10.23, for a total value of $51,150.00. Following the completion of the transaction, the insider directly owned 1,346,053 shares in the company, valued at approximately $13,770,122.19. This represents a 0.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 168,332 shares of company stock worth $1,678,971 over the last three months. Corporate insiders own 4.35% of the company’s stock.
Institutional Trading of Xeris Biopharma
A number of institutional investors and hedge funds have recently modified their holdings of XERS. BlackRock Inc. bought a new stake in Xeris Biopharma in the 2nd quarter valued at $115,042,000. Wellington Management Group LLP boosted its position in shares of Xeris Biopharma by 8.9% during the 2nd quarter. Wellington Management Group LLP now owns 2,365,103 shares of the company’s stock valued at $18,732,000 after acquiring an additional 193,749 shares in the last quarter. Legal & General Group Plc acquired a new stake in shares of Xeris Biopharma during the 2nd quarter valued at about $15,941,000. Parkman Healthcare Partners LLC acquired a new stake in shares of Xeris Biopharma during the 2nd quarter valued at about $14,316,000. Finally, Algert Global LLC increased its stake in Xeris Biopharma by 50.6% in the second quarter. Algert Global LLC now owns 1,742,942 shares of the company’s stock valued at $13,804,000 after acquiring an additional 585,984 shares during the period. 42.75% of the stock is currently owned by institutional investors.
Xeris Biopharma Company Profile
Xeris Biopharma is a commercial-stage biopharmaceutical company focused on developing and providing treatments for people with endocrine and other serious health conditions. Its products include Gvoke, a ready-to-use glucagon product for the treatment of severe hypoglycemia, and Recorlev, a treatment for adults with endogenous hypercortisolemia associated with Cushing syndrome when surgery is not an option or has not been curative. The company also develops drug-delivery technologies intended to make medicines easier to store and administer.
Recommended Stories
- Five stocks we like better than Xeris Biopharma
- NVIDIA’s Earnings Were Strong, But Can the Next CEO Keep the Momentum Going?
- SpaceX’s Historic Starship Catch Raises a Bigger Question About Its AI Spending
- AMD Bets $8.2B on Physical AI: Could Robotics Be Its Next Growth Frontier?
- 3 Stocks Flashing Buy Signals With Historical Win Rates Above 85% After the Sell-Off
Receive News & Ratings for Xeris Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
